MedNexus
2020年 · 第133卷第09期
出版日期 2020-05-01电子版 ￥0.00元
MedNexus
- 全部
- Editorial
- Special Article
- Original Article
- Study Protocol
- Clinical Guideline
- Consensus Statement
- Review Article
- Perspective
- Viewpoint
- Clinical Observation
- Rapid Report
- Correspondence
Editorial
开放获取
科学对抗新型冠状病毒病2019(COVID-19)Wang Jian-Wei, Cao Bin, Wang Chen
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000777
摘要
2019年12月，中国湖北省武汉市出现群组不明原因病毒性肺炎病例。这一突发事件引起全球关注，世界卫生组织（世卫组织）宣布此次疫情为国际关注的突发公共卫生事件。在国家卫生健康委员会的组织下，多学科工作组共同努力确定病原体，并迅速确定了一种被世卫组织命名为2019新型冠状病毒（2019新型冠状病毒）的新型冠状病毒是此次传染性流行病的病原体。
Special Article
开放获取
来自中国的声音：新型冠状病毒及相关疾病命名法Wu Gui-Zhen, Wang Jian-Wei, Xu Jian-Qing
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000787
摘要
自2019年12月初以来，新型冠状病毒引发了肺炎疫情，夺去了2000多人的生命，截至2020年2月23日，中国已有超过77,000例确诊感染病例。[
Original Article
开放获取
一种导致人类严重肺炎的新型冠状病毒的鉴定：一项描述性研究Ren Li-Li, Wang Ye-Ming, Wu Zhi-Qiang, Xiang Zi-Chun, Guo Li, Xu Teng, Jiang Yong-Zhong, Xiong Yan, Li Yong-Jun, Li Xing-Wang 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000722
摘要
Background:
Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally. Here, we report a novel batorigin CoV causing severe and fatal pneumonia in humans.
Methods:
We collected clinical data and bronchoalveolar lavage (BAL) specimens from five patients with severe pneumonia from Wuhan Jinyintan Hospital, Hubei province, China. Nucleic acids of the BAL were extracted and subjected to next-generation sequencing. Virus isolation was carried out, and maximum-likelihood phylogenetic trees were constructed.
Results:
Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome. Chest radiography revealed diffuse opacities and consolidation. One of these patients died. Sequence results revealed the presence of a previously unknown β-CoV strain in all five patients, with 99.8% to 99.9% nucleotide identities among the isolates. These isolates showed 79.0% nucleotide identity with the sequence of SARS-CoV (GenBank NC_004718) and 51.8% identity with the sequence of MERS-CoV (GenBank NC_019843). The virus is phylogenetically closest to a bat SARS-like CoV (SL-ZC45, GenBank MG772933) with 87.6% to 87.7% nucleotide identity, but is in a separate clade. Moreover, these viruses have a single intact open reading frame gene 8, as a further indicator of bat-origin CoVs. However, the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV, indicating that these viruses might use the same receptor.
Conclusion:
A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans.
开放获取
湖北省三级医院新型冠状病毒病例临床特点Liu Kui, Fang Yuan-Yuan, Deng Yan, Liu Wei, Wang Mei-Fang, Ma Jing-Ping, Xiao Wei, Wang Ying-Nan, Zhong Min-Hua, Li Cheng-Hong 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000744
摘要
Background:
The 2019 novel coronavirus (2019-nCoV) causing an outbreak of pneumonia in Wuhan, Hubei province of China was isolated in January 2020. This study aims to investigate its epidemiologic history, and analyze the clinical characteristics, treatment regimens, and prognosis of patients infected with 2019-nCoV during this outbreak.
Methods:
Clinical data from 137 2019-nCoV-infected patients admitted to the respiratory departments of nine tertiary hospitals in Hubei province from December 30, 2019 to January 24, 2020 were retrospectively collected, including general status, clinical manifestations, laboratory test results, imaging characteristics, and treatment regimens.
Results:
None of the 137 patients (61 males, 76 females, aged 20-83 years, median age 57 years) had a definite history of exposure to Huanan Seafood Wholesale Market. Major initial symptoms included fever (112/137, 81.8%), coughing (66/137, 48.2%), and muscle pain or fatigue (44/137, 32.1%), with other, less typical initial symptoms observed at low frequency, including heart palpitations, diarrhea, and headache. Nearly 80% of the patients had normal or decreased white blood cell counts, and 72.3% (99/137) had lymphocytopenia. Lung involvement was present in all cases, with most chest computed tomography scans showing lesions in multiple lung lobes, some of which were dense; ground-glass opacity co-existed with consolidation shadows or cord-like shadows. Given the lack of effective drugs, treatment focused on symptomatic and respiratory support. Immunoglobulin G was delivered to some critically ill patients according to their conditions. Systemic corticosteroid treatment did not show significant benefits. Notably, early respiratory support facilitated disease recovery and improved prognosis. The risk of death was primarily associated with age, underlying chronic diseases, and median interval from the appearance of initial symptoms to dyspnea.
Conclusions:
The majority of patients with 2019-nCoV pneumonia present with fever as the first symptom, and most of them still showed typical manifestations of viral pneumonia on chest imaging. Middle-aged and elderly patients with underlying comorbidities are susceptible to respiratory failure and may have a poorer prognosis.
开放获取
2019年新型冠状病毒病住院患者疾病结局相关因素分析Liu Wei, Tao Zhao-Wu, Wang Lei, Yuan Ming-Li, Liu Kui, Zhou Ling, Wei Shuang, Deng Yan, Liu Jing, Liu Hui-Guo 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000775
摘要
Background
Since early December 2019, the 2019 novel coronavirus disease (COVID-19) has caused pneumonia epidemic in Wuhan, Hubei province of China. This study aimed to investigate the factors affecting the progression of pneumonia in COVID-19 patients. Associated results will be used to evaluate the prognosis and to find the optimal treatment regimens for COVID-19 pneumonia.
Methods
Patients tested positive for the COVID-19 based on nucleic acid detection were included in this study. Patients were admitted to 3 tertiary hospitals in Wuhan between December 30, 2019, and January 15, 2020. Individual data, laboratory indices, imaging characteristics, and clinical data were collected, and statistical analysis was performed. Based on clinical typing results, the patients were divided into a progression group or an improvement/stabilization group. Continuous variables were analyzed using independent samples t-test or Mann-Whitney U test. Categorical variables were analyzed using Chi-squared test or Fisher’s exact test. Logistic regression analysis was performed to explore the risk factors for disease progression.
Results
Seventy-eight patients with COVID-19-induced pneumonia met the inclusion criteria and were included in this study. Efficacy evaluation at 2 weeks after hospitalization indicated that 11 patients (14.1%) had deteriorated, and 67 patients (85.9%) had improved/stabilized. The patients in the progression group were significantly older than those in the disease improvement/stabilization group (66 [51, 70] vs. 37 [32, 41] years, U= 4.932, P= 0.001). The progression group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group (27.3% vs. 3.0%, χ2 = 9.291, P = 0.018). For all the 78 patients, fever was the most common initial symptom, and the maximum body temperature at admission was significantly higher in the progression group than in the improvement/stabilization group (38.2 [37.8, 38.6] vs. 37.5 [37.0, 38.4]°C, U= 2.057, P= 0.027). Moreover, the proportion of patients with respiratory failure (54.5% vs. 20.9%, χ2 = 5.611, P = 0.028) and respiratory rate (34 [18, 48] vs. 24 [16, 60] breaths/min, U= 4.030, P = 0.004) were significantly higher in the progression group than in the improvement/stabilization group. C-reactive protein was significantly elevated in the progression group compared to the improvement/stabilization group (38.9 [14.3, 64.8] vs. 10.6 [1.9, 33.1] mg/L, U= 1.315, P= 0.024). Albumin was significantly lower in the progression group than in the improvement/stabilization group (36.62 ± 6.60 vs. 41.27 ± 4.55 g/L, U = 2.843, P = 0.006). Patients in the progression group were more likely to receive high-level respiratory support than in the improvement/stabilization group (χ2 = 16.01, P = 0.001). Multivariate logistic analysis indicated that age (odds ratio [OR], 8.546; 95% confidence interval [CI]: 1.628-44.864; P = 0.011), history of smoking (OR, 14.285; 95% CI: 1.577-25.000; P= 0.018), maximum body temperature at admission (OR, 8.999; 95% CI: 1.036-78.147, P= 0.046), respiratory failure (OR, 8.772, 95% CI: 1.942-40.000; P = 0.016), albumin (OR, 7.353, 95% CI: 1.098-50.000; P = 0.003), and C-reactive protein (OR, 10.530; 95% CI: 1.224-34.701, P = 0.028) were risk factors for disease progression.
Conclusions
Several factors that led to the progression of COVID-19 pneumonia were identified, including age, history of smoking, maximum body temperature at admission, respiratory failure, albumin, and C-reactive protein. These results can be used to further enhance the ability of management of COVID-19 pneumonia.
开放获取
2019年新型冠状病毒病康复患者病毒RNA的持久性和清除情况Ling Yun, Xu Shui-Bao, Lin Yi-Xiao, Tian Di, Zhu Zhao-Qin, Dai Fa-Hui, Wu Fan, Song Zhi-Gang, Huang Wei, Chen Jun 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000774
摘要
Background:
A patient’s infectivity is determined by the presence of the virus in different body fluids, secretions, and excreta. The persistence and clearance of viral RNA from different specimens of patients with 2019 novel coronavirus disease (COVID-19) remain unclear. This study analyzed the clearance time and factors influencing 2019 novel coronavirus (2019-nCoV) RNA in different samples from patients with COVID-19, providing further evidence to improve the management of patients during convalescence.
Methods:
The clinical data and laboratory test results of convalescent patients with COVID-19 who were admitted to from January 20, 2020 to February 10, 2020 were collected retrospectively. The reverse transcription polymerase chain reaction (RT-PCR) results for patients’ oropharyngeal swab, stool, urine, and serum samples were collected and analyzed. Convalescent patients refer to recovered non-febrile patients without respiratory symptoms who had two successive (minimum 24 h sampling interval) negative RT-PCR results for viral RNA from oropharyngeal swabs. The effects of cluster of differentiation 4 (CD4)+ T lymphocytes, inflammatory indicators, and glucocorticoid treatment on viral nucleic acid clearance were analyzed.
Results:
In the 292 confirmed cases, 66 patients recovered after treatment and were included in our study. In total, 28 (42.4%) women and 38 men (57.6%) with a median age of 44.0 (34.0-62.0) years were analyzed. After in-hospital treatment, patients’ inflammatory indicators decreased with improved clinical condition. The median time from the onset of symptoms to first negative RT-PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0-11.0) days. By February 10, 2020, 11 convalescent patients (16.7%) still tested positive for viral RNA from stool specimens and the other 55 patients’ stool specimens were negative for 2019-nCoV following a median duration of 11.0 (9.0-16.0) days after symptom onset. Among these 55 patients, 43 had a longer duration until stool specimens were negative for viral RNA than for throat swabs, with a median delay of 2.0 (1.0-4.0) days. Results for only four (6.9%) urine samples were positive for viral nucleic acid out of 58 cases; viral RNA was still present in three patients’ urine specimens after throat swabs were negative. Using a multiple linear regression model (F = 2.669, P = 0.044, and adjusted R2 = 0.122), the analysis showed that the CD4+ T lymphocyte count may help predict the duration of viral RNA detection in patients’ stools (t = -2.699, P = 0.010). The duration of viral RNA detection from oropharyngeal swabs and fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (15 days vs. 8.0 days, respectively; t= 2.550, P = 0.013) and the duration of viral RNA detection in fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (20 days vs. 11 days, respectively; t = 4.631, P < 0.001). There was no statistically significant difference in inflammatory indicators between patients with positive fecal viral RNA test results and those with negative results (P > 0.05).
Conclusions:
In brief, as the clearance of viral RNA in patients’ stools was delayed compared to that in oropharyngeal swabs, it is important to identify viral RNA in feces during convalescence. Because of the delayed clearance of viral RNA in the glucocorticoid treatment group, glucocorticoids are not recommended in the treatment of COVID-19, especially for mild disease. The duration of RNA detection may relate to host cell immunity.
开放获取
中国武汉新冠肺炎疫情分布及其与人口迁出的相关性Chen Ze-Liang, Zhang Qi, Lu Yi, Guo Zhong-Min, Zhang Xi, Zhang Wen-Jun, Guo Cheng, Liao Cong-Hui, Li Qian-Lin, Han Xiao-Hu 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000782
摘要
Background:
The ongoing new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) outbreak is spreading in China, but it has not yet reached its peak. Five million people emigrated from Wuhan before lockdown, potentially representing a source of virus infection. Determining case distribution and its correlation with population emigration from Wuhan in the early stage of the epidemic is of great importance for early warning and for the prevention of future outbreaks.
Methods:
The official case report on the COVID-19 epidemic was collected as of January 30, 2020. Time and location information on COVID-19 cases was extracted and analyzed using ArcGIS and WinBUGS software. Data on population migration from Wuhan city and Hubei province were extracted from Baidu Qianxi, and their correlation with the number of cases was analyzed.
Results:
The COVID-19 confirmed and death cases in Hubei province accounted for 59.91% (5806/9692) and 95.77% (204/213) of the total cases in China, respectively. Hot spot provinces included Sichuan and Yunnan, which are adjacent to Hubei. The time risk of Hubei province on the following day was 1.960 times that on the previous day. The number of cases in some cities was relatively low, but the time risk appeared to be continuously rising. The correlation coefficient between the provincial number of cases and emigration from Wuhan was up to 0.943. The lockdown of 17 cities in Hubei province and the implementation of nationwide control measures efficiently prevented an exponential growth in the number of cases.
Conclusions:
The population that emigrated from Wuhan was the main infection source in other cities and provinces. Some cities with a low number of cases showed a rapid increase in case load. Owing to the upcoming Spring Festival return wave, understanding the risk trends in different regions is crucial to ensure preparedness at both the individual and organization levels and to prevent new outbreaks.
开放获取
在2019-新型冠状病毒相关冠状病毒模型中重新利用临床批准的治疗2019冠状病毒疾病的药物Fan Hua-Hao, Wang Li-Qin, Liu Wen-Li, An Xiao-Ping, Liu Zhen-Dong, He Xiao-Qi, Song Li-Hua, Tong Yi-Gang
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000797
摘要
Background:
Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV-related coronavirus model.
Methods:
A 2019-nCoV-related pangolin coronavirus GX_P2V/pangolin/2017/Guangxi was described. Whether GX_P2V uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA)-mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2V infection. The anti-viral activities and anti-viral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively.
Results:
The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhanhu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs, including cepharanthine (CEP), selamectin, and mefloquine hydrochloride, exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 μmol/L. The viral RNA yield in cells treated with 10 μmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ± 0.02] × 10-4vs. 1.00 ± 0.12, t= 150.38, P < 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 μmol/L CEP at 48 h p.i. Furthermore, we found CEP had potent anti-viral activities against both viral entry (0.46 ± 0.12, vs.1.00 ± 0.37, t = 2.42, P < 0.05) and viral replication ([6.18 ± 0.95] × 10-4vs. 1.00 ± 0.43, t= 3.98, P < 0.05).
Conclusions:
Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin, and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.
开放获取
子痫前期患者中晚期肠道菌群失调Wang Jing, Shi Zhong-Hua, Yang Jing, Wei Yuan, Wang Xiao-Ye, Zhao Yang-Yu
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000734
摘要
Background:
Preeclampsia (PE) is a serious complication that affects maternal and perinatal outcomes. However, the mechanisms have not been fully explained. This study was designed to analyze longitudinal gut microbiota alterations in pregnant women with and without PE in the second (T2) and third trimesters (T3).
Methods:
In this nested case-control study, which was conducted at Nanjing Maternity and Child Health Care Hospital, fecal samples from 25 PE patients (25 fecal samples obtained in T2 and 15 fecal samples obtained in T3) and 25 matched healthy controls (25 fecal samples obtained in T2 and 22 fecal samples obtained in T3) were collected, and the microbiota were analyzed using 16S rRNA gene sequencing. The diversity and composition of the microbiota of PE cases and controls were compared.
Results:
No significant differences in diversity were found between the PE and control groups (P > 0.05). In the control group, from T2 to T3, the relative abundances of Proteobacteria (median [Q1, Q3]: 2.25% [1.24%, 3.30%] vs. 0.64% [0.20%, 1.20%], Z = -3.880, P < 0.05), and Tenericutes (median [Q1, Q3]: 0.12% [0.03%, 3.10%] vs. 0.03% [0.02%, 0.17%], Z= -2.369, P < 0.05) decreased significantly. In the PE group, the relative abundance of Bacteroidetes in T2 was lower than in T3 (median [Q1, Q3]: 18.16% [12.99%, 30.46%] vs. 31.09% [19.89%, 46.06%], Z= -2.417, P < 0.05). In T2, the relative abundances of mircrobiota showed no significant differences between the PE group and the control group. However, in T3, the relative abundance of Firmicutes was significantly lower in the PE group than in the control group (mean ± standard deviation: 60.62% ± 15.17% vs. 75.57% ± 11.53%, t= -3.405, P < 0.05). The relative abundances of Bacteroidetes, Proteobacteria, and Enterobacteriaceae were significantly higher in the PE group than in the control group (median [Q1, Q3]: 31.09% [19.89%, 46.06%] vs. 18.24% [12.90%, 32.04%], Z=-2.537, P < 0.05; 1.52% [1.05%, 2.61%] vs. 0.64% [0.20%, 1.20%], Z=-3.310, P < 0.05; 0.75% [0.20%, 1.00%] vs. 0.01% [0.004%, 0.023%], Z = -4.152, P < 0.05). Linear discriminant analysis combined effect size measurements analysis showed that the relative abundances of the phylum Bacteroidetes, class Bacteroidia and order Bacteroidales were increased in the PE group, while those of the phylum Firmicutes, the class Clostridia, the order Clostridiales, and the genus unidentified Lachnospiraceae were decreased in the PE group; and these differences were identified as taxonomic biomarkers of PE in T3.
Conclusion:
From T2 to T3, there was an obvious alteration in the gut microbiota. The gut microbiota of PE patients in T3 was significantly different from that of the control group.
开放获取
中国高血压患者膳食钠摄入量与血压变异性的关系Wang Chi, Liu Tong-Bo, Mu Lei, Wang Miao, Li Yao, Yao Si-Yu, Zhao Mao-Xiang, Xue Hao
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000740
摘要
Background:
The association between dietary sodium intake and blood pressure variability (BPV) in hypertensive patients remains unclear. The objective of this study was to demonstrate whether dietary sodium intake is a predictor of elevated BPV in Chinese patients with hypertension.
Methods:
A total of 235 patients with essential hypertension were enrolled in the Department of Cardiology, Chinese People’s Liberation Army (PLA) General Hospital in 2018 to 2019, all of whom underwent 24-h ambulatory blood pressure monitoring. BPV was calculated as the standard deviation (SD), coefficient of variation (CV), variation independent of mean (VIM) of blood pressure measurements, respectively, and divided into diurnal systolic BPV (SBPV), diurnal diastolic BPV (DBPV), nocturnal SBPV, and nocturnal DBPV. 24-h urine samples were collected to measure 24-h urine sodium excretion, which represents dietary sodium intake. The relationship between dietary sodium intake and BPV was analyzed by using Spearman correlations and multiple linear regression analysis.
Results:
Nocturnal SBPV-SD, CV, VIM, and nocturnal DBPV-SD in the high urine sodium excretion group were significantly higher than those in the medium and low urine sodium excretion groups, whereas diurnal SBPV-SD, CV, VIM, diurnal DBPV-SD, CV, VIM, and nocturnal DBPV-CV, VIM were not. Using the Spearman correlation analysis, we found a linear correlation between 24-h urine sodium excretion and nocturnal SBPV-SD, CV, VIM (SD, r= 0.22, P= 0.001; CV, r= 0.17, P= 0.009; VIM, r= 0.16, P = 0.020), nocturnal DBPV-SD (r = 0.21, P = 0.001), respectively. After further adjusting for confounding factors by multiple linear regression, the positive correlations remained between 24-h urine sodium excretion and nocturnal SBPV-SD, CV, VIM (SD, β= 0.224, P < 0.001; CV, β= 0.211, P= 0.001; VIM, β= 0.213, P= 0.001), nocturnal DBPV (SD, β= 0.215, P= 0.001), respectively.
Conclusions:
Dietary sodium intake is associated with nocturnal SBPV in Chinese patients with hypertension.
开放获取
右美托咪定通过胆碱能抗炎途径减轻实验性重症急性胰腺炎大鼠模型的炎症和胰腺损伤Huang Dong-Ya, Li Qiang, Shi Chen-Yuan, Hou Chao-Qun, Miao Yi, Shen Hong-Bing
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000766
摘要
Background:
Excessive inflammatory responses play a critical role in the development of severe acute pancreatitis (SAP), and controlling such inflammation is vital for managing this often fatal disease. Dexmedetomidine has been reported to possess protective properties in inflammatory diseases. Therefore, this study aimed to investigate whether dexmedetomidine pre-treatment exerts an anti-inflammatory effect in rats with SAP induced by sodium taurocholate, and if so, to determine the potential mechanism.
Methods:
SAP was induced with sodium taurocholate. Rats received an intraperitoneal injection of dexmedetomidine 30 min before sodium taurocholate administration. α-bungarotoxin, a selective alpha-7 nicotinic acetylcholine receptor (α7nAchR) antagonist, was injected intra-peritoneally 30 min before dexmedetomidine administration. The role of the vagus nerve was evaluated by performing unilateral cervical vagotomy before the administration of dexmedetomidine. Efferent discharge of the vagal nerve was recorded by the BL-420F Data Acquisition & Analysis System. Six hours after onset, serum pro-inflammatory cytokine (tumor necrosis factor α [TNF-α] and interleukin 6 [IL-6]) levels and amylase levels were determined using an enzyme-linked immunosorbent assay and an automated biochemical analyzer, respectively. Histopathological changes in the pancreas were observed after hematoxylin and eosin staining and scored according to Schmidt criteria.
Results:
Pre-treatment with dexmedetomidine significantly decreased serum levels of TNF-α, IL-6, and amylase, strongly alleviating pathological pancreatic injury in the rat model of SAP (TNF-α: 174.2 ± 30.2 vs. 256.1±42.4 pg/ml; IL-6: 293.3 ± 46.8 vs. 421.7 ± 48.3 pg/ml; amylase: 2102.3 ± 165.3 vs. 3186.4 ± 245.2 U/L). However, the anti-inflammatory and pancreatic protective effects were abolished after vagotomy or pre-administration of α-bungarotoxin. Dexmedetomidine also significantly increased the discharge frequency and amplitude of the cervical vagus nerve in the SAP rat model (discharge frequency: 456.8 ± 50.3 vs. 332.4 ± 25.1 Hz; discharge amplitude: 33.4 ± 5.3 vs. 20.5 ± 2.9 μV).
Conclusions:
Dexmedetomidine administration attenuated the systemic inflammatory response and local pancreatic injury caused by SAP in rats through the cholinergic anti-inflammatory pathway involving vagus-and α7nAChR-dependent mechanisms.
Study Protocol
开放获取
2019年严重冠状病毒疾病患者糖皮质激素治疗的有效性：一项随机对照试验方案Qin Yuan-Yuan, Zhou Yi-Hong, Lu Yan-Qiu, Sun Feng, Yang Sen, Harypursat Vijay, Chen Yao-Kai
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000791
摘要
Background:
At the end of 2019, a novel coronavirus outbreak causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV). The effectiveness of adjunctive glucocorticoid therapy in the management of 2019-nCoV-infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation.
Methods:
The present study will be conducted as an open-labeled, randomized, controlled trial. We will enrol 48 subjects from Chongqing Public Health Medical Center. Each eligible subject will be assigned to an intervention group (methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days) or a control group (no glucocorticoid use) randomly, at a 1:1 ratio. Subjects in both groups will be invited for 28 days of follow-up which will be scheduled at four consecutive visit points. We will use the clinical improvement rate as our primary endpoint. Secondary endpoints include the timing of clinical improvement after intervention, duration of mechanical ventilation, duration of hospitalization, overall incidence of adverse events, as well as rate of adverse events at each visit, and mortality at 2 and 4 weeks.
Discussion:
The present coronavirus outbreak is the third serious global coronavirus outbreak in the past two decades. Oral and parenteral glucocorticoids have been used in the management of severe respiratory symptoms in coronavirus-infected patients in the past. However, there remains no definitive evidence in the literature for or against the utilization of systemic glucocorticoids in seriously ill patients with coronavirus-related severe respiratory disease, or indeed in other types of severe respiratory disease. In this study, we hope to discover evidence either supporting or opposing the systemic therapeutic administration of glucocorticoids in patients with severe coronavirus disease 2019.
Trial registration:
ClinicalTrials.gov, ChiCTR2000029386, http://www.chictr.org.cn/showproj.aspx?proj=48777.
Clinical Guideline
开放获取
新型冠状病毒肺炎病诊疗方案（试行第7版）National Health Commission &, National Administration of Traditional Chinese Medicine
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000819
摘要
自2019年12月以来，湖北省武汉市发现多例新型冠状病毒肺炎（COVID-19）病例。随着疫情蔓延，我国其他地区和其他国家也发现了此类病例。新冠肺炎作为一种急性呼吸道传染病，已被纳入《中华人民共和国传染病防治法》规定的乙类传染病，按甲类传染病管理。通过采取一系列防控和医疗救治措施，国内疫情上升势头得到一定遏制，大部分省份疫情有所缓解，但境外发病呈上升趋势。随着对本病临床表现和病理认识的增加，以及诊疗经验的积累，为进一步加强本病的早诊早治，提高治愈率，降低病死率，尽可能避免院内感染并注意境外输入病例引起的传播，我们修订了新型冠状病毒肺炎病诊疗方案（试行第六版）到新型冠状病毒肺炎病诊疗方案（试行第7版）.
Consensus Statement
开放获取
2019冠状病毒病流行骨科急诊管理原则专家共识Tang Pei-Fu, Hou Zhi-Yong, Wu Xin-Bao, Zhang Chang-Qing, Wang Jun-Wen, Xing Xin, Shao Zeng-Wu, Yu Ai-Xi, Wang Gang, Chen Bin 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000810
摘要
2019年12月以来，武汉多名患者持续感染不明原因肺炎。[
Review Article
开放获取
激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌的内分泌和靶向治疗进展Shen Le-Sang, Jin Xiao-Yan, Wang Xu-Meng, Tou Lai-Zhen, Huang Jian
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000745
摘要
Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is superior to tamoxifen, and fulvestrant is a better option for patients previously exposed to endocrine therapy. Targeted drugs, such as cyclindependent kinases (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, and histone deacetylase (HDAC) inhibitors, play a significant role in the present and show a promising future. With the application of CDK4/6 inhibitors becoming common, mechanisms of acquired resistance to them should also be taken into consideration.
Perspective
开放获取
新型冠状病毒肺炎病患者的无创呼吸支持：临床疗效和降低感染传播风险Xia Jin-Gen, Zhao Jian-Ping, Cheng Zhen-Shun, Hu Yi, Duan Jun, Zhan Qing-Yuan
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000761
摘要
由一种被称为2019新型冠状病毒病（COVID-19）的新型冠状病毒引起的肺炎[
开放获取
从严重急性呼吸综合征相关冠状病毒到2019年新型冠状病毒疫情：早期流行的相似性和未来趋势预测Chen Ze-Liang, Zhang Wen-Jun, Lu Yi, Guo Cheng, Guo Zhong-Min, Liao Cong-Hui, Zhang Xi, Zhang Yi, Han Xiao-Hu, Li Qian-Lin 等
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000776
摘要
新出现的传染病对全球人类公共健康构成严重威胁。[
开放获取
2019年新型冠状病毒病体外膜肺氧合支持：适应症、时机和实施Li Min, Gu Si-Chao, Wu Xiao-Jing, Xia Jin-Gen, Zhang Yi, Zhan Qing-Yuan
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000778
摘要
2019年新型冠状病毒病（COVID-19）由于其人际传播和针对下呼吸道的强侵袭性，已在湖北省和全国所有地区迅速传播。[
开放获取
2019年冠状病毒病爆发六周：是时候考虑阻止新的人畜共患感染出现的策略了Harypursat Vijay, Chen Yao-Kai
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000760
摘要
过去已知冠状病毒是人类轻度上呼吸道感染的病原体，类似于成人和儿童中由人鼻病毒诱导的普遍存在且相对良性的“普通感冒”型上呼吸道疾病。继2003年在中国爆发严重急性呼吸综合征（SARS）和2012年在中东爆发中东呼吸综合征（MERS）后，全球开始关注新型人类冠状病毒的致病性和流行性/大流行潜力，一些专家预测新型冠状病毒可能再次跨越物种障碍，并为人类带来未来大流行潜力的感染。[
Viewpoint
开放获取
个人对新型冠状病毒肺炎的认识Kang Han-Yu-Jie, Wang Yi-Shan, Tong Zhao-Hui
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000757
摘要
部分感染新型冠状病毒（2019新型冠状病毒）患者流行病学史不清楚，病毒潜伏期可长达2周，甚至更长。在潜伏感染期间或感染后的潜伏期，疾病可能具有传染性。与流感病例一样，一些患者仅发展为上呼吸道感染，而其他患有严重疾病的患者发展为肺炎。患者可无发热、轻度咳嗽或明显呼吸道症状，可有头痛或胃肠道症状。部分患者表现为起病隐匿，进展缓慢，并不表现为患病。因此，他们可能不会受到关注或被识别。部分重症或危重症患者可表现为中低热，但也可无明显发热。
Clinical Observation
开放获取
2019年新型冠状病毒确诊无症状感染者1例Luo Si-Hui, Liu Wei, Liu Zhen-Jun, Zheng Xue-Ying, Hong Chang-Xing, Liu Zhi-Rong, Liu Jian, Weng Jian-Ping
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000798
摘要
自2019年12月以来，2019新型冠状病毒（2019新型冠状病毒）感染疫情已成为全球重大突发公共卫生事件。约40%的2019新型冠状病毒感染确诊病例（通过病毒RNA检测阳性判断）最初无症状，但后来出现了冠状病毒疾病-2019（新冠肺炎）的明显临床症状。[
开放获取
活检中炎性脱髓鞘疾病的临床病理特征Wei Jia, Xu Wei-Wei, Wang Ke-Jie, Fu Yong-Juan, Piao Yue-Shan, Lu De-Hong
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000738
摘要
中枢神经系统（CNS）的炎性脱髓鞘疾病（IDD）在世界各地都有发生，是年轻人非创伤性神经残疾的主要原因。[
Rapid Report
开放获取
单细胞RNA测序数据表明血管紧张素转换酶2在2019-新型冠状病毒感染患者肾功能损害中的作用Deng Yi-Yao, Zheng Ying, Cai Guang-Yan, Chen Xiang-Mei, Hong Quan
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000783
摘要
世界卫生组织最近宣布2019-新型冠状病毒（2019新型冠状病毒）为全球突发公共卫生事件。黄等人[
Correspondence
开放获取
利巴韦林联合干扰素α、洛匹那韦/利托那韦联合干扰素α和利巴韦林联合洛匹那韦/利托那韦联合干扰素α治疗轻中度新型冠状病毒病患者的有效性和安全性比较2019：研究方案Zeng Yan-Ming, Xu Xiao-Lei, He Xiao-Qing, Tang Sheng-Quan, Li Yao, Huang Yin-Qiu, Harypursat Vijay, Chen Yao-Kai
中华医学杂志英文版2020年 133卷 09期
DOI: 10.1097/CM9.0000000000000790
摘要
致编辑：2019年底，由2019新型冠状病毒引起的2019年新型冠状病毒病（COVID-19）爆发，导致广泛的新型冠状病毒病。此次新冠肺炎疫情发生在中国2020年春节期间，这是一个以中国境内大规模人口流动而闻名的时期。这导致了大量受感染的患者，这是个别旅行者中多次与人接触的结果。
本期目次
下载本期封面 下载本期目录
